Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy2J Mouse Model of Congenital Muscular Dystrophy

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Yu, Qing ^a   Sali, Arpana ^a   van der Meulen, Jack ^a   Creeden, Brittany K ^a   Gordish Dressman, Heather ^a   Rutkowski, Anne ^b   Rayavarapu, Sree ^a   Uaesoontrachoon, Kitipong ^a   Huynh, Tony ^a   Nagaraju, Kanneboyina ^a   Spurney, Christopher F ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b Cure CMD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMIGAPIL; DIBENZO(B,F)OXEPIN-10-YLMETHYL-METHYL-PROP-2-YNYL-AMINE; LAMININ; LAMININ ALPHA2; OXEPINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING RATE; CONTROLLED STUDY; DIAPHRAGM; DRUG DOSE COMPARISON; FORELIMB; GASTROCNEMIUS MUSCLE; GRIP STRENGTH; LUNG FIBROSIS; MOUSE; MOVEMENT (PHYSIOLOGY); MUSCLE STRENGTH; MUSCULAR DYSTROPHY; NONHUMAN; REST; TREATMENT RESPONSE; ANIMAL; DEFICIENCY; DRUG EFFECTS; FIBROSIS; GENETICS; HINDLIMB; HUMAN; KNOCKOUT MOUSE; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, ANIMAL; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SKELETAL MUSCLE;

MUS;

ADMINISTRATION, ORAL; ANIMALS; FIBROSIS; FORELIMB; HINDLIMB; HUMANS; LAMININ; MICE; MICE, KNOCKOUT; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, ANIMAL; OXEPINS; RESPIRATORY RATE;

EID: 84878800366     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065468     Document Type: Article

References (19)

1. Collins J, Bonnemann CG, (2010) Congenital muscular dystrophies: toward molecular therapeutic interventions. Curr Neurol Neurosci Rep 10: 83-91.
2. Tome FM, Evangelista T, Leclerc A, Sunada Y, Manole E, et al. (1994) Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III 317: 351-357.
3. Muntoni F, Voit T, (2004) The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul Disord 14: 635-649.
4. Hayashi YK, Tezak Z, Momoi T, Nonaka I, Garcia CA, et al. (2001) Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 11: 350-359.
5. Kuang W, Xu H, Vachon PH, Liu L, Loechel F, et al. (1998) Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. J Clin Invest 102: 844-852.
6. Xu H, Wu XR, Wewer UM, Engvall E, (1994) Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat Genet 8: 297-302.
7. Miyagoe Y, Hanaoka K, Nonaka I, Hayasaka M, Nabeshima Y, et al. (1997) Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett 415: 33-39.
8. Girgenrath M, Dominov JA, Kostek CA, Miller JB, (2004) Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J Clin Invest 114: 1635-1639.
9. Dominov JA, Kravetz AJ, Ardelt M, Kostek CA, Beermann ML, et al. (2005) Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice. Hum Mol Genet 14: 1029-1040.
10. Erb M, Meinen S, Barzaghi P, Sumanovski LT, Courdier-Fruh I, et al. (2009) Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. J Pharmacol Exp Ther 331: 787-795.
11. Sagot Y, Toni N, Perrelet D, Lurot S, King B, et al. (2000) An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br J Pharmacol 131: 721-728.
12. Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, et al. (2006) TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5: 1013-1020.
13. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, et al. (2007) Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 69: 776-784.
14. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, et al. (2009) Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 39: 591-602.
15. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, et al. (2000) Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 97: 9209-9214.
16. Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, et al. (1998) Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273: 19086-19092.
17. Raben N, Nagaraju K, Lee E, Plotz P, (2000) Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene. Neuromuscul Disord 10: 283-291.
18. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, et al. (2011) Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 16: 87-95.
19. Waldmeier PC, Boulton AA, Cools AR, Kato AC, Tatton WG (2000) Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl: 197-214.